Abstract: A beauty/medication patch including a substrate, an outer layer, and a medication lotion; the outer layer being made of a degradable material being disposed on the substrate; one or a plurality of micro-probe array being disposed on a surface of the outer layer; the medication lotion being coated between the substrate and the outer layer, and/or admixed in the substrate; the patch being attached to a human skin, the micro-probe array piercing through a stratum corneum layer of the human skin and naturally being degraded by human skin or absorbed and metabolized by a human body; and the medication lotion penetrating into the skin and being absorbed by the human skin.

Abstract: Disclosed are delivery agents for selective delivery to leukocytes. The leukocyte-selective delivery agents comprise a targeting moiety that selectively binds LFA-I, a non-protein carrier moiety covalently linked to the targeting moiety and a therapeutic agent associated with the carrier moiety. The non-protein carrier moiety comprises a liposome, a micelle, or a polymeric nanoparticle comprised of PLA or PLGA. The delivery agent may be further selective for activated leukocytes by using a targeting moiety that selectively binds LFA-I in its activated conformation. The targeting moiety may comprise an antibody or functional fragment thereof such as an scFV. Appropriate therapeutic agents include a nucleic acid, a small molecule, a polypeptide, and an antibody or functional fragment thereof. Additional examples of therapeutic agents are a small RNA, an antagomir, an LNA, or an antisense oligonucleotide. One such therapeutic agent is an RNA interference molecule such as siRNA, dsRNA, stRNA, shRNA, miRNA.

Abstract: The present invention includes compositions and methods for the controlled delivery of active agents, e.g., drugs, based on one or more release triggers found in the environment in which the active agent-loaded particle is located. The composition and methods include a polymer network having a polymer cross-linked by peptides that include one or more proteolytic cleavage sites.

Abstract: The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.

Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Abstract: A therapeutic agent which carries a peptide sequence containing a mammalian cell adhesion sequence can be used to inhibit or treat diseases associated with intracellular formation of protein fibrillar inclusions or aggregates, to inhibit the intracellular formation of protein fibrillar inclusions or aggregates, and to disaggregate pre-formed intracellular protein fibrillar inclusions or aggregates. Filamentous bacteriophage which displays a non-filamentous bacteriophage RGD cell adhesion sequence on its surface, but not an antibody or non-filamentous bacteriophage antigen other than said RGD cell adhesion sequence, is a preferred embodiment of such a therapeutic agent.

Abstract: The present invention relates to kits for formulating a cosmetic product, containing an aqueous composition and at least one water-soluble anhydrous film, the aqueous composition and the film(s) being mixed together extemporaneously to form the cosmetic product.

Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.

Abstract: A spinning solution composition which provides regenerated silk fiber that exhibits a strength and elongation close to those of natural silk fiber, is rapidly degradable in vivo, and can be caused to have ability to gradually release a drug to prevent inflammation; a process for producing such regenerated silk fiber by use of the composition; and regenerated silk fiber obtained through the process.

Abstract: This disclosure relates to compositions for delivering agents to a subject, and in particular, to compositions for delivery of therapeutic agents or diagnostic agents in the presence or absence of targeting moieties. In part, this disclosure relates to compositions comprising a hydrophobic group with a first end and a second end, a first metal binding domain linked to the hydrophobic group, a metal ion capable of being chelated to the first metal binding domain, and an agent linked to a second metal binding domain capable of chelating to the metal ion.

Abstract: The invention relates to a method of selectively targeting an active agent (or agent capable of becoming an active agent) to apoptotic cells in a vertebrate, comprising administering to said vertebrate a system comprising an arsenoxide (or arsenoxide equivalent) compound and said agent, wherein said system selectively targets apoptotic cells.

Abstract: A foamed delivery system having at least two components: a foam and an additive that is associated with, carried by or delivered by the foam. The foam is a stable foam that has a liquid matrix, gas bubbles and a structuring agent that forms a lamellar or vesicular cage structure without generating a gel imparting a rubbery texture. The lamellar cage structure entraps at least a substantial portion of the gas bubbles and liquid matrix therein to retain the gas bubbles and liquid in a sufficiently compact structure that substantially prevents drainage of the liquid matrix and coalescence and creaming of the gas bubbles to maintain stability of the foam even when the foam is subjected to heat shock. Combined with the stable foam structure the distribution and release of the additive during application is significantly improved.

Abstract: A tablet for removing tongue coating, wherein the tablet contains highly soluble saccharide and lowly soluble saccharide, the highly soluble saccharide and the lowly soluble saccharide are water-soluble, of water-soluble saccharides contained as the primary component in the tablet, the highly soluble saccharide has the highest solubility in water at 37° C., the highly soluble saccharide is a saccharide having the highest solubility in water at 37° C. among the water-soluble saccharides contained in the tablet as the main components, the lowly soluble saccharide is a saccharide having the lowest solubility in water at 37° C. among the water-soluble saccharides contained in the tablet as the main components, and the difference between the solubility of the highly soluble saccharide in water at 37° C. and the solubility of the lowly soluble saccharide in water at 37° C. is 10% by weight or more.

Abstract: The invention relates to an anionic polyamide functionalized with at least one tryptophan unit, -Trp, said tryptophan unit being linked to the polyamide by an amide function separated from the backbone by a linker arm, the polyamide being a chain selected from the group constituted of the following polymers: L being selected from the group constituted of a single bond, a —CH2— group or a —CH2CH2— group, -Trp being an L and/or D tryptophan residue produced from the coupling between the amine of the tryptophan or of a tryptophan derivative, selected from the group constituted of tryptophanol, tryptophanamide and alkali-metal cation salts thereof, and an acid borne by the polyamide. The present invention also relates to a pharmaceutical composition containing one of the polyamides according to the invention.

Abstract: pH modulated films and methods of their preparation. The film compositions include at least one component having a non-neutral pH when combined with water; and a pH modulated polymer system selected to reduce or prevent synerisis when combined with the non-neutral component in combination with aqueous media. The films demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, extrusion process, or other process that maintains the required uniformity of the film.

Abstract: An altered capsid protein of a primate-infective papovavirus in which a foreign peptide sandwiched by 1 to several glycine residues at each end is inserted into at least one of the DE-loop or the HI-loop of the capsid protein of the primate-infective papovavirus, and a virus-like particle formed from the altered capsid protein.

Abstract: Poly-pseudo-lysine conjugates have been shown to be able to penetrate into human skin and are proposed for both therapeutic and cosmetic treatments by topical application, e.g. change of skin pigmentation.

Abstract: The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders.

Abstract: The present invention relates to the field of polymer chemistry and more particularly to encapsulated peptides and uses thereof.

Abstract: Use of a composition comprising oil bodies in the preparation of a formulation for administration to a mammal wherein said composition comprises oil curd 5 extracted from grain plant tissue, said oil curd comprising an aqueous dispersion of oil bodies and associated extrinsic protein material. Preferably, the oil curd is extracted from oat seed material. The composition has useful properties in improving the stability of 10 formulations, in particular in emulsifying such formulations and in improving the aesthetic acceptability of a formulation. Also, the compositions are useful in the delivery of actives into the skin &/or hair and in the regulation of the condition of the skin &/or hair. 15 Processes for the preparation of said composition and formulations are also disclosed.

Abstract: We add discontinuous regions of Extra Cellular Matrix (ECM) to a biodegradable scaffold. Hereby it is possible to combine the range of physical properties the scaffold can offer with the reconstructive properties of the ECM. The optimal amount of discrete ECM material for each application is disclosed and this concentration is equally distributed in the dressing hence avoiding unnecessary high concentrations of ECM. In addition to the effect of the ECM, the porous structure of the base material provides the cells with a structure for in-growth.

Abstract: The secretion or biological activity of Flaviviruses, as well as the biological activity of NS1 protein from Flavivirus-infected cells, can be inhibited by contacting the cells or the protein with cholesterol inhibitors, sphingolipid inhibitors, glycosphingolipid inhibitors, or molecules comprising an amphipathic, amphiphilic, or hydrophobic region which interacts with NS1 protein.

Abstract: Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject, in which the permeabilizing peptide is a tight junction modulating peptide (TJMP), a TJMP analogue, a conjugate of a TJMP, a conjugate of a TJMP analogue, or complexes thereof. The permeabilizing agent reversibly enhances mucosal epithelial paracellular transport, typically by modulating epithelial junctional structure and/or physiology at a mucosal epithelial surface in the subject.

Abstract: The present invention relates to compositions of natural extracts in oil medium, prepared in non-free-flowing formulations, and encapsuled in hard gelatin capsules, without post-fill sealing. These compositions comprise a therapeutically effective amount of at least one natural extract in oil medium, the composition suitable for treating a medical condition, and at least one oil-absorbent ingredient in powder form. More specifically, the natural extract in the composition can be an extract of Wrightia tinctoria, which is suitable for treating medical conditions, such as, but not limited to, relief from pain, psoriasis, eczema, spondolytis, acne and wound care. The invention also provides a method for encapsulating the natural extracts in oil medium compositions, compounded in a non-free-flowing formulation, in hard gelatin capsules without the need for post-fill sealing.

Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.

Abstract: Compositions for coating biological and non-biological surfaces, which minimize or prevent cell-cell contact and tissue adhesion, and methods of preparation and use thereof are disclosed. Embodiments include polyethylene glycol/polylysine (PEG/PLL) block or comb-type copolymers with high molecular weight PLL (greater than 1000, more preferably greater than 100,000); PEG/PLL copolymers in which the PLL is a dendrimer which is attached to one end of the PEG; and multilayer compositions including alternating layers of polycationic and polyanionic materials. The multi-layer polymeric material is formed by the ionic interactions of a polycation and a polyanion. The molecular weights of the individual materials are selected such that the PEG portion of the copolymer inhibits cellular interactions, and the PLL portion adheres well to tissues.

Abstract: (Modified) rice endosperm protein is used as novel protective hydrocolloid for active ingredients, especially fat-soluble active ingredients and/or colorants. Included are compositions comprising (modified) rice endosperm protein and at least one active ingredient and to their manufacture, as well as to the (modified) rice endosperm protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions, and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a (modified) rice endosperm protein and such a composition, respectively.

Abstract: The membrane scaffold proteins (MSP) of the present invention assemble with hydrophobic or partially hydrophobic proteins to form soluble nanoscale particles which preserve native structure and function; they are improved over liposomes and detergent micelles, both in terms of stability and preservation of biological activity and native conformation. In the presence of phospholipid, MSPs form nanoscopic phospholipid bilayer disks, with the MSP stabilizing the particle at the perimeter of the bilayer domain. The particle bilayer structure allows manipulation of incorporated proteins in solution or on solid supports, including for use with such surface-sensitive techniques as scanning probe microscopy or surface plasmon resonance. The nanoscale particles, which are robust in terms of integrity and maintenance of biological activity of incorporated proteins, facilitate pharmaceutical and biological research, structure/function correlations, structure determinations, bioseparations, and drug discovery.

Abstract: The invention relates to a therapeutic composition comprising a therapeutically effective amount of one or more therapeutic agents and a nasal mucosa absorption-enhancing amount of one or more tight junction agonists. The invention further relates to a method of treating a subject comprising intranasally administering the composition of the invention to the subject.

Abstract: The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

Abstract: The invention provides elastomeric polymer networks and semi-interpenetrating networks in which a linear PEA, PEUR or PEU polymer is crosslinked by ester or alpha-amino-acid containing cross-linkers that polymerize upon exposure to active species. Bioabsorbable elastomeric internal fixation devices fabricated using such polymer networks and semi-interpenetrating networks are useful for in vivo implant and delivery of a variety of different types of molecules in a time release fashion. Alpha-amino-acid containing ester amide cross-linkers are also provided by the invention.

Abstract: The present disclosure relates to osteoinductive putties and other implantable compositions for repair of bone defects and other medical uses. Specifically, the technology pertains to carriers for use in implantable compositions, such as osteoinductive putties. The osteoinductive putties are made entirely from donor tissue such as demineralized bone matrix, and the putties have excellent physical properties. The present disclosure relates to osteoinductive putties, carriers, compositions, implants, kits, methods of making and methods of using any of the foregoing.

Abstract: Disclosed are compositions and methods useful for targeting tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins. The compositions and methods are based on peptide sequences that selectively bind to and home to tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tissue experiencing angiogenesis or to cells or tissue expressing ?v integrins.

Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.

Abstract: The present invention provides targeting lipids of structure L100—linker—L101 ??(CI), where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.

Abstract: The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding domains are covalently linked. The first and second substrate-binding domains are covalently coupled to at least one hydrophobic interaction tag, negatively charged interaction tag, or positively charged interaction tag. When the substrate-binding domains are combined and coated onto the tissue or medical device, the hydrophobic interaction tags interact with each other and the charged interaction tags interact with the oppositely charged interaction tags or the oppositely charged substrate binding polymers, to form a macromolecular network of non-covalently coupled substrate-binding domains to load the target molecule onto the tissue or medical device.

Abstract: Improved methods and preparations are provided for ocular administration of therapeutic drugs. The preparations include respective quantities of a drug and a peptide which enhances transport of the drug across ocular tissues. The drug and peptide components may be separately administered or used as a mixture. The preferred peptide is NC-1059 (SEQ. ID NO. 1).

Abstract: The present invention provides for concentrated aqueous silk fibroin solutions and an all-aqueous mode for preparation of concentrated aqueous fibroin solutions that avoids the use of organic solvents, direct additives, or harsh chemicals. The invention further provides for the use of these solutions in production of materials, e.g., fibers, films, foams, meshes, scaffolds and hydrogels.

Abstract: The present invention provides a process for producing ?-(3-(1,3/1,6)-D-glucan from a cellular source comprising the steps of alkali extraction of the cellular source; water extraction; acid extraction; and water extraction, where at least one step of water extraction includes pasteurization by steam injection to a temperature of about 100° C. for 15 to about 30 minutes. The solid component produced comprises at least ?-70% 1 (1,3/1,6)-D-glucan by dry weight. The present invention also provides a process of producing mannan and manno-protein complexes comprising the steps of collecting a liquid phase obtained in one an alkali extraction step of the ?(3-(1,3/1,6)-D-glucan process; adjusting the pH of the liquid phase to about 5.0-8.0 with an acid; pasteurizing the liquid phase by steam injection to a temperature of about 100° C. for 15 to about 30 minutes; and isolating the mannans and manno-proteins complexes from the pasteurized liquid phase.

Abstract: Some aspects of the present disclosure relate to methods for treating a tissue by forming a low-swelling biodegradable hydrogel in situ adherent to the tissue. In embodiments the hydrogel exhibits negative swelling, i.e., shrinking. Such treatments may be utilized to in cosmetic or reconstructive surgery, in sphincter augmentation, treating nerve inflammation, and the like.

Abstract: Metadherin, a protein that controls metastasis, and variants of metadherin are described. DNA sequences encoding the same and methods of production are described. Therapies involving the application of metadherin, binding agents that bind to metadherin, such as antibodies, and expression modulating agents, such as siRNA, are described. The use of metadherin or metadherin variants for delivering desired substances to particular lung tissue is described. A method of diagnosing metastatic cells based on the presence of metadherin is described.

Abstract: A bioresorbable and mineralized material for filling osseous defects includes a native and/or renatured collagen matrix of congregated collagen chains, in which essentially only a surface of the congregated collagen chains is mineralized. A shaped article for filling osseous defects includes such a material. A method for producing a shaped article for filling osseous defects from a liquid medium, includes the steps of deposition of a mineral substance, preferably from its dissolved ionogenic components, on a collagen matrix, precipitation of the mineralized collagen matrix, separation of the mineralized collagen matrix, transfer of the mineralized collagen matrix to a suspension, transfer of the suspension to a mold defining the shaped article, and freeze-drying of the suspension in the mold.

Abstract: The present invention relates to different uses of an RHCC peptide and/or a fragment thereof. Said RHCC peptide and/or fragment thereof enables an uptake and association of a drug and/or a substance into a cavity of said peptide and/or fragment, for the delivery and release of such a substance and/or drug to a target site of interest, or for removal of a substance from a fluid or a non-fluid matter, such as from a bodily tissue or a bodily fluid. An RHCC peptide and/or a fragment thereof, may also in one context be used in the production of nanoparticles, or as a catalyst in a chemical reaction. In a preferred aspect, said RHCC peptide and/or fragment thereof, comprises a drug delivery system for the delivery of a drug to a site of interest in a living body.

Abstract: The present invention provides new biopolymers which mimic the properties of natural polysaccharides found in vivo. The inventive polysaccharides can be used as viscosupplements, viscoelastics, tissue space fillers, and/or anti-adhesive agents. Also provided are pharmaceutical compositions comprising the inventive polymers and methods of using them including, for example, in the treatment of arthritic and sport-injured knee joints; in reconstruction or cosmetic procedures, intervertebral disc repair, treatment of vocal cord problems, treatment of urinary incontinence, and prevention of adhesion formation following abdominal or gynecological surgery.

Abstract: The invention provides, in one aspect, compositions for delivering a bioactive metal ion to a mammal, the compositions comprising (a) an effective amount of a source of the bioactive metal ion, (b) a phosphoprotein preparation obtained by partially cross linking a partial hydrolysate of casein or a caseinate, and (c) one or more physiologically acceptable diluents or carriers. Also provided are compositions for remineralising tooth enamel and/or for treating or preventing dental caries, tooth erosion, dentinal hypersensitivity or gingivitis in a mammal, wherein the compositions comprise an effective amount of such a phosphoprotein preparation, in combination with one or more carriers or diluents. In related aspects, the invention provides methods of using such compositions. Also provided are novel phosphoprotein preparations suitable for use in such compositions and methods.

Abstract: Nanoparticles, the particle matrix of which is based on at least one protein and has at least one active agent embedded therein and methods of producing the nanoparticles with at least one active agent embedded in the protein matrix are disclosed. The use of the nanoparticles for the treatment of tumours, in particular for the treatment of tumours which are resistant to chemical medicaments is also disclosed.

Abstract: The present invention relates to a soluble hydrophobic-core carrier composition comprising (i) a linear polymeric backbone; (ii) a plurality of hydrophilic polymeric protective chains covalently linked and pendant to the polymeric backbone and (iii) at least one hydrophobic moiety covalently linked and pendant to the polymeric backbone. In certain embodiments, the weight ratio of hydrophilic protective chains to hydrophobic moieties in the carrier is at least 15:1. In other embodiments, at least 90% of the residues of the polymeric backbone are coupled to a hydrophilic polymeric protective chain or a hydrophobic moiety. In other embodiments, the composition further comprises (iv) a hydrophobic load molecule dissociably linked to the hydrophobic moiety of the carrier.

Abstract: The present invention provides a carrier capable of highly efficiently introducing a compound into cells with low cytotoxicity, which contains peptide lipids represented by the following formula, and a method for introducing a compound into cells using the carrier: wherein R1 is an amino acid or peptide having 1-10 amino acid residues, R2 is a side chain of any amino acid, provided that R2 has a carboxyl group, the carboxyl group may be an ester with a hydrocarbon group having 1-30 carbon atoms, R3 is a hydrocarbon group having 1-30 carbon atoms.

Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.

Abstract: The present invention describes a curable bone cement. The cement comprises a curable polymeric binder and a filler, and is capable of curing without substantial evolution of heat on exposure to a curing agent. The binder comprises phenol groups which are capable of reacting in order to cure the cement.